RIGL
Rigel Pharmaceuticals, Inc.
Biotechnology
Market Cap$485M
5Y Perf.+34.2%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
RIGL vs DBVT vs HALO vs IMVT vs ABBV
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.68B
5Y Perf.+168.6%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+6.1%
ABBV
AbbVie Inc.
Drug Manufacturers - General
Market Cap$358.42B
5Y Perf.+118.7%
RIGL vs DBVT vs HALO vs IMVT vs ABBV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RIGL | DBVT | HALO | IMVT | ABBV |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Drug Manufacturers - General |
| Market Cap | $485M | $1712.35T | $7.68B | $5.53B | $358.42B |
| Revenue (TTM) | $300M | $0.00 | $1.40B | $0.00 | $61.16B |
| Net Income (TTM) | $364M | $-168M | $317M | $-464M | $4.23B |
| Gross Margin | 93.4% | — | 81.9% | — | 70.2% |
| Operating Margin | 41.6% | — | 58.4% | — | 26.7% |
| Forward P/E | 6.0x | — | 8.1x | — | 14.3x |
| Total Debt | $53M | $22M | $0.00 | $98K | $69.07B |
| Cash & Equiv. | $41M | $194M | $134M | $714M | $5.23B |
RIGL vs DBVT vs HALO vs IMVT vs ABBV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RIGL
DBVT
HALO
IMVT
ABBV
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Rigel Pharmaceutica… (RIGL) | 100 | 134.2 | +34.2% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| Halozyme Therapeuti… (HALO) | 100 | 268.6 | +168.6% |
| Immunovant, Inc. (IMVT) | 100 | 106.1 | +6.1% |
| AbbVie Inc. (ABBV) | 100 | 218.7 | +118.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RIGL vs DBVT vs HALO vs IMVT vs ABBV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RIGL leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. AbbVie Inc. is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. DBVT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
RIGL
Rigel Pharmaceuticals, Inc.
The Growth Play
RIGL carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 64.1%, EPS growth 18.7%, 3Y rev CAGR 34.8%
- 64.1% revenue growth vs DBVT's -100.0%
- Lower P/E (6.0x vs 14.3x)
- 121.5% margin vs DBVT's 0.3%
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Momentum Pick
DBVT ranks third and is worth considering specifically for momentum.
- +110.4% vs HALO's -7.1%
Best for: momentum
HALO
Halozyme Therapeutics, Inc.
The Defensive Pick
HALO is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.56, current ratio 4.66x
- Beta 0.56, current ratio 4.66x
Best for: sleep-well-at-night and defensive
IMVT
Immunovant, Inc.
The Healthcare Pick
Among these 5 stocks, IMVT doesn't own a clear edge in any measured category.
Best for: healthcare exposure
ABBV
AbbVie Inc.
The Income Pick
ABBV is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 13 yrs, beta 0.34, yield 3.2%
- 295.5% 10Y total return vs HALO's 5.7%
- Beta 0.34 vs IMVT's 1.37
- 3.2% yield; 13-year raise streak; the other 4 pay no meaningful dividend
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RIGL | 64.1% revenue growth vs DBVT's -100.0% |
| Value | RIGL | Lower P/E (6.0x vs 14.3x) |
| Quality / Margins | RIGL | 121.5% margin vs DBVT's 0.3% |
| Stability / Safety | ABBV | Beta 0.34 vs IMVT's 1.37 |
| Dividends | ABBV | 3.2% yield; 13-year raise streak; the other 4 pay no meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs HALO's -7.1% |
| Efficiency (ROA) | RIGL | 99.3% ROA vs DBVT's -89.0% |
RIGL vs DBVT vs HALO vs IMVT vs ABBV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FY 2025
Segment breakdown not available.
FY 2025
RIGL vs DBVT vs HALO vs IMVT vs ABBV — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRIGLLAGGINGIMVT
Who Leads Where
RIGL leads in 2 of 6 categories
HALO leads 1 • ABBV leads 1 • DBVT leads 0 • IMVT leads 0 • 2 tied
Explore the data ↓IMVTImmunovant, Inc.
0leads
DBVTDBV Technologies S.A.
0leads
ABBVAbbVie Inc.
1leads
HALOHalozyme Therapeutics…
1leads
RIGLRigel Pharmaceuticals…
2leads
6 Total Categories
CATEGORYLEADERvs HALOvs ABBVMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HALO3/6
Valuation MetricsMultiples, price ratios, and targets
RIGL4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
RIGL2/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
ABBV1/1
Income & Cash Flow (Last 12 Months)
HALO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ABBV and IMVT operate at a comparable scale, with $61.2B and $0 in trailing revenue. RIGL is the more profitable business, keeping 121.5% of every revenue dollar as net income compared to ABBV's 6.9%. On growth, HALO holds the edge at +51.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RIGLRigel Pharmaceuti… | DBVTDBV Technologies … | HALOHalozyme Therapeu… | IMVTImmunovant, Inc. | ABBVAbbVie Inc. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $300M | $0 | $1.4B | $0 | $61.2B |
| EBITDAEarnings before interest/tax | $126M | -$112M | $945M | -$487M | $24.5B |
| Net IncomeAfter-tax profit | $364M | -$168M | $317M | -$464M | $4.2B |
| Free Cash FlowCash after capex | $79M | -$151M | $645M | -$423M | $18.7B |
| Gross MarginGross profit ÷ Revenue | +93.4% | — | +81.9% | — | +70.2% |
| Operating MarginEBIT ÷ Revenue | +41.6% | — | +58.4% | — | +26.7% |
| Net MarginNet income ÷ Revenue | +121.5% | — | +22.7% | — | +6.9% |
| FCF MarginFCF ÷ Revenue | +26.4% | — | +46.2% | — | +30.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.3% | — | +51.6% | — | +10.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -30.2% | +91.5% | -2.1% | +19.7% | +57.4% |
HALO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
RIGL leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 1.3x trailing earnings, RIGL trades at a 98% valuation discount to ABBV's 85.5x P/E. On an enterprise value basis, RIGL's 3.9x EV/EBITDA is more attractive than ABBV's 15.0x.
| Metric | RIGLRigel Pharmaceuti… | DBVTDBV Technologies … | HALOHalozyme Therapeu… | IMVTImmunovant, Inc. | ABBVAbbVie Inc. |
|---|---|---|---|---|---|
| Market CapShares × price | $485M | $1712.35T | $7.7B | $5.5B | $358.4B |
| Enterprise ValueMkt cap + debt − cash | $498M | $1712.35T | $7.5B | $4.8B | $422.3B |
| Trailing P/EPrice ÷ TTM EPS | 1.35x | -0.76x | 25.46x | -9.97x | 85.50x |
| Forward P/EPrice ÷ next-FY EPS est. | 6.04x | — | 8.09x | — | 14.28x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 1.11x | — | — |
| EV / EBITDAEnterprise value multiple | 3.90x | — | 8.34x | — | 14.96x |
| Price / SalesMarket cap ÷ Revenue | 1.65x | — | 5.50x | — | 5.86x |
| Price / BookPrice ÷ Book value/share | 1.26x | 0.66x | 165.47x | 5.83x | — |
| Price / FCFMarket cap ÷ FCF | 6.42x | — | 11.91x | — | 20.12x |
RIGL leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
Evenly matched — RIGL and HALO each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
ABBV delivers a 62.1% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $-130 for DBVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RIGL's 0.14x. On the Piotroski fundamental quality scale (0–9), RIGL scores 6/9 vs IMVT's 2/9, reflecting solid financial health.
| Metric | RIGLRigel Pharmaceuti… | DBVTDBV Technologies … | HALOHalozyme Therapeu… | IMVTImmunovant, Inc. | ABBVAbbVie Inc. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +147.0% | -130.2% | +6.5% | -47.1% | +62.1% |
| ROA (TTM)Return on assets | +99.3% | -89.0% | +12.5% | -44.1% | +3.1% |
| ROICReturn on invested capital | +45.8% | — | +73.4% | — | +23.9% |
| ROCEReturn on capital employed | +48.7% | -145.7% | +38.2% | -66.1% | +21.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 5 | 2 | 6 |
| Debt / EquityFinancial leverage | 0.14x | 0.13x | — | 0.00x | — |
| Net DebtTotal debt minus cash | $13M | -$172M | -$134M | -$714M | $63.8B |
| Cash & Equiv.Liquid assets | $41M | $194M | $134M | $714M | $5.2B |
| Total DebtShort + long-term debt | $53M | $22M | $0 | $98,000 | $69.1B |
| Interest CoverageEBIT ÷ Interest expense | 30.74x | -189.82x | 46.08x | — | 3.28x |
Evenly matched — RIGL and HALO each lead in 3 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
RIGL leads this category, winning 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ABBV five years ago would be worth $20,131 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs HALO's -7.1%. The 3-year compound annual growth rate (CAGR) favors RIGL at 30.2% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | RIGLRigel Pharmaceuti… | DBVTDBV Technologies … | HALOHalozyme Therapeu… | IMVTImmunovant, Inc. | ABBVAbbVie Inc. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -37.3% | +4.9% | -7.3% | +5.1% | -10.1% |
| 1-Year ReturnPast 12 months | +42.1% | +110.4% | -7.1% | +96.1% | +11.3% |
| 3-Year ReturnCumulative with dividends | +120.5% | +19.7% | +115.3% | +40.9% | +50.4% |
| 5-Year ReturnCumulative with dividends | -22.4% | -69.1% | +37.0% | +62.4% | +101.3% |
| 10-Year ReturnCumulative with dividends | +7.1% | -87.0% | +570.7% | +173.6% | +295.5% |
| CAGR (3Y)Annualised 3-year return | +30.2% | +6.2% | +29.1% | +12.1% | +14.6% |
RIGL leads this category, winning 2 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IMVT and ABBV each lead in 1 of 2 comparable metrics.
Risk & Volatility
ABBV is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs RIGL's 50.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RIGLRigel Pharmaceuti… | DBVTDBV Technologies … | HALOHalozyme Therapeu… | IMVTImmunovant, Inc. | ABBVAbbVie Inc. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.03x | 1.26x | 0.56x | 1.37x | 0.34x |
| 52-Week HighHighest price in past year | $52.24 | $26.18 | $82.22 | $30.09 | $244.81 |
| 52-Week LowLowest price in past year | $16.88 | $7.53 | $47.50 | $13.36 | $176.57 |
| % of 52W HighCurrent price vs 52-week peak | +50.2% | +76.3% | +79.3% | +90.5% | +82.8% |
| RSI (14)Momentum oscillator 0–100 | 34.0 | 48.1 | 52.4 | 60.2 | 46.8 |
| Avg Volume (50D)Average daily shares traded | 361K | 252K | 1.4M | 1.4M | 5.8M |
Evenly matched — IMVT and ABBV each lead in 1 of 2 comparable metrics.
Analyst Outlook
ABBV leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: RIGL as "Buy", DBVT as "Buy", HALO as "Buy", IMVT as "Buy", ABBV as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 20.2% for HALO (target: $78). ABBV is the only dividend payer here at 3.24% yield — a key consideration for income-focused portfolios.
| Metric | RIGLRigel Pharmaceuti… | DBVTDBV Technologies … | HALOHalozyme Therapeu… | IMVTImmunovant, Inc. | ABBVAbbVie Inc. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $40.00 | $46.33 | $78.33 | $45.50 | $256.64 |
| # AnalystsCovering analysts | 15 | 15 | 27 | 23 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +3.2% |
| Dividend StreakConsecutive years of raises | — | 0 | — | — | 13 |
| Dividend / ShareAnnual DPS | — | — | — | — | $6.57 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +4.5% | 0.0% | +0.3% |
ABBV leads this category, winning 1 of 1 comparable metric.
Key Takeaway
RIGL leads in 2 of 6 categories (Valuation Metrics, Total Returns). HALO leads in 1 (Income & Cash Flow). 2 tied.
Best OverallRigel Pharmaceuticals, Inc. (RIGL)Leads 2 of 6 categories
Loading custom metrics...
RIGL vs DBVT vs HALO vs IMVT vs ABBV: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RIGL or DBVT or HALO or IMVT or ABBV a better buy right now?
For growth investors, Rigel Pharmaceuticals, Inc.
(RIGL) is the stronger pick with 64. 1% revenue growth year-over-year, versus 8. 6% for AbbVie Inc. (ABBV). Rigel Pharmaceuticals, Inc. (RIGL) offers the better valuation at 1. 3x trailing P/E (6. 0x forward), making it the more compelling value choice. Analysts rate Rigel Pharmaceuticals, Inc. (RIGL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RIGL or DBVT or HALO or IMVT or ABBV?
On trailing P/E, Rigel Pharmaceuticals, Inc.
(RIGL) is the cheapest at 1. 3x versus AbbVie Inc. at 85. 5x. On forward P/E, Rigel Pharmaceuticals, Inc. is actually cheaper at 6. 0x.
03Which is the better long-term investment — RIGL or DBVT or HALO or IMVT or ABBV?
Over the past 5 years, AbbVie Inc.
(ABBV) delivered a total return of +101. 3%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HALO returned +570. 7% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RIGL or DBVT or HALO or IMVT or ABBV?
By beta (market sensitivity over 5 years), AbbVie Inc.
(ABBV) is the lower-risk stock at 0. 34β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 306% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 14% for Rigel Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RIGL or DBVT or HALO or IMVT or ABBV?
By revenue growth (latest reported year), Rigel Pharmaceuticals, Inc.
(RIGL) is pulling ahead at 64. 1% versus 8. 6% for AbbVie Inc. (ABBV). On earnings-per-share growth, the picture is similar: Rigel Pharmaceuticals, Inc. grew EPS 1868% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, RIGL leads at 34. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RIGL or DBVT or HALO or IMVT or ABBV?
Rigel Pharmaceuticals, Inc.
(RIGL) is the more profitable company, earning 124. 7% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 124. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — RIGL leads at 93. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RIGL or DBVT or HALO or IMVT or ABBV more undervalued right now?
On forward earnings alone, Rigel Pharmaceuticals, Inc.
(RIGL) trades at 6. 0x forward P/E versus 14. 3x for AbbVie Inc. — 8. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — RIGL or DBVT or HALO or IMVT or ABBV?
In this comparison, ABBV (3.
2% yield) pays a dividend. RIGL, DBVT, HALO, IMVT do not pay a meaningful dividend and should not be held primarily for income.
09Is RIGL or DBVT or HALO or IMVT or ABBV better for a retirement portfolio?
For long-horizon retirement investors, AbbVie Inc.
(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RIGL and DBVT and HALO and IMVT and ABBV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RIGL is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; HALO is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while RIGL, DBVT, HALO, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.